Characterization of Ovarian Cancer Cell Lines as In Vivo Models for Preclinical Studies

Hernandez, Lidia; Kim, Marianne K.; Lyle, L. Tiffany; Bunch, Kristen P.; House, Carrie D.; Ning, Franklin; Noonan, Anne M.; Annunziata, Christina M.

doi:10.1016/j.ygyno.2016.05.028

Cited by 122Ovarian cancer diagnosis and treatmentCancer Cells and MetastasisReproductive Biology and Fertility

Characterization of Ovarian Cancer Cell Lines as In Vivo Models for Preclinical Studies

Open access

Hernandez, Lidia, Kim, Marianne K., Lyle, L. Tiffany, Bunch, Kristen P., House, Carrie D., Ning, Franklin, Noonan, Anne M., Annunziata, Christina M.·2016·Gynecologic Oncology

DOI 10.1016/j.ygyno.2016.05.028PMC PMC4961516

Open this paper in CoChat — free account

Abstract

Objective The value of cell lines for pre-clinical work lies in choosing those with similar characteristics. Selection of cell lines is typically based on patient history, histological subtype at diagnosis, mutation patterns, or signaling pathways. Although recent studies established consensus regarding molecular characteristics of ovarian cancer cell lines, data on in vivo tumorigenicity remains only sporadically available, impeding translation of in vitro work to xenograft models.Methods We introduced 18 ovarian cancer cell lines into athymic nude mice through subcutaneous, intraperitoneal, and ovary intrabursal routes, and observed tumor development over 6weeks. We also profiled cell line gene expression and identified differentially expressed gene sets based on their ability to form tumors in the subcutaneous or intraperitoneal locations. Representative cell lines were further subjected to proteomic analyses.Results Ovarian cancer cell lines showed variable ability to grow in mice when implanted subcutaneous, intraperitoneal, or intrabursal. While some cell lines grew well in both SC and IP locations, others showed a strong propensity to grow in one location only. Gene expression profiles suggested that cell lines showing preference for IP growth had gene expression patterns more similar to primary tumors.Conclusions We report the tumorigenicity of 17 human ovarian cancer cell lines and one mouse cell line in three distinct anatomical locations, and associated gene networks. Growth patterns and histopathology, linked to molecular characteristics, provide a valuable resource to the research community, and better guide the choice of cell lines for in vitro studies to translate efficiently into xenograft testing.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2016.05.028

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Ovarian cancer cell lines show variable ability to grow in nude mice when implanted either subcutaneously, intraperitoneally or intrabursally.
“Ovarian cancer cell lines show variable ability to grow in nude mice when implanted either subcutaneously (SC), intraperitoneally (IP) or intrabursally (Hernandez et al., 2016).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hernandez et al., 2016

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854 · see citing works
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works
Ovarian Cancer Development and Metastasis
Lengyel, E. R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,679 · see citing works
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,472 · see citing works
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. D. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,426 · see citing works
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies
Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70404-1 · Cited by 939 · see citing works
Absence of HeLa Cell Contamination in 169 Cell Lines Derived From Human Tumors2
Fogh, J., Wright, W. C., & Loveless, J. D. (1977) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/58.2.209 · Cited by 663 · see citing works
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593 · see citing works
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.
Hamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. W., Whang‐Peng, J., Rogan, A. M., Green, W. R., & Ozols, R. F. (1983) · PubMed · Cited by 539 · see citing works
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang‐Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., & Ozols, R. F. (1987) · PubMed · Cited by 501 · see citing works
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403 · cited 2× · see citing works
“Recent studies have reported comprehensive data gathered for the most commonly available ovarian cancer cell lines (8, 9).”
Exome Capture Reveals ZNF423 and CEP164 Mutations, Linking Renal Ciliopathies to DNA Damage Response Signaling
Chaki, M., Airik, R., Ghosh, A. K., Giles, R. H., Chen, R., Slaats, G. G. G., Wang, H., Hurd, T. W., Zhou, W., Cluckey, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.028 · Cited by 374 · see citing works
Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Pradeep, S., Kim, S. W., Wu, S. Y., Nishimura, M., Chaluvally–Raghavan, P., Miyake, T. M., Pecot, C. V., Kim, S.-J., Choi, H. J., Bischoff, F. Z., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.002 · Cited by 306 · see citing works
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.
Bénard, J., Silva, J. D., Blois, M. C. D., Boyer, P. J. J., Duvillard, P., Chiric, E., & RIOU, G. F. (1985) · PubMed · Cited by 287 · see citing works
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Langdon, S. P., Lawrie, S. S., Hay, F. G., Hawkes, M. M., McDonald, A. W., Hayward, I. P., Schol, D. J., Hilgers, J., Leonard, R. C., & Smyth, J. F. (1988) · PubMed · Cited by 269 · see citing works
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C. M., Prentice, L., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072162 · Cited by 248 · see citing works
In vivo tumor growth of high-grade serous ovarian cancer cell lines
Mitra, A. K., Davis, D. A., Tomar, S., Roy, L., Main, H. G., Xie, J., Lantvit, D. D., Cárdenas, H., Fang, F., Liu, Y., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.040 · Cited by 214 · see citing works
Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer
Colombo, P., Fabbro, M., Theillet, C. G., Bibeau, F., Rouanet, P., & Ray-Coquard, I. L. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.017 · Cited by 188 · see citing works
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer
Schilder, R. J., HALL, L., Monks, A. P., Handel, L. M., Fornace, A. J., Ozols, R. F., Fojo, A. T., & Hamilton, T. C. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450306 · Cited by 185 · see citing works
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma
Cooke, S. L., Ng, C. K. Y., Melnyk, N., García, M. J., Hardcastle, T. J., Temple, J., Langdon, S. P., Huntsman, D. D., & Brenton, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.245 · Cited by 178 · see citing works
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors
Chenevix‐Trench, G., Ryland, G. L., Hunter, S. M., Doyle, M., Caramia, F., Li, J., Rowley, S. M., Christie, M., Allan, P. E., Stephens, A. N., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0210-y · Cited by 165 · see citing works
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129 · see citing works
DNA Methylation in Ovarian Cancer
Ahluwalia, A., Hurteau, J. A., Bigsby, R. M., & Nephew, K. P. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6284 · Cited by 118 · see citing works
Role of maspin in cancer
Berardi, R., Morgese, F., Onofri, A., Mazzanti, P., Pistelli, M., Ballatore, Z., Savini, A., Lisa, M. D., Caramanti, M., Rinaldi, S., et al. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-8 · Cited by 114 · see citing works
Evidence for a Dualistic Model of High-grade Serous Carcinoma
Howitt, B. E., Hanamornroongruang, S., Lin, D. I., Conner, J. E., Schulte, S., Horowitz, N. S., Crum, C. P., & Meserve, E. E. K. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000369 · Cited by 111 · see citing works
Gene Expression Correlations in Human Cancer Cell Lines Define Molecular Interaction Networks for Epithelial Phenotype
Kohn, K. W., Zeeberg, B. M., Reinhold, W. C., & Pommier, Y. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099269 · Cited by 109 · see citing works
Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy
Pepa, C. D., Tonini, G., Santini, D., Losito, S., Pisano, C., Napoli, M. D., Cecere, S. C., Gargiulo, P., & Pignata, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.003 · Cited by 97 · see citing works
Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research
Elias, K. M., Emori, M. M., Papp, E., MacDuffie, E., Konecny, G. E., Velculescu, V. E., & Drapkin, R. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.017 · Cited by 82 · see citing works
Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9
Lo, P. H. Y., Leung, A. C. C., Kwok, C. Y. C., Cheung, W. S. Y., Ko, J. M. Y., Yang, L., Law, S. Y.-K., Wang, L. D., Li, J., Stanbridge, E. J., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209767 · Cited by 80 · see citing works
o,p′-DDD (mitotane) therapy of adrenal cortical carcinoma. Observations on drug dosage, toxicity, and steroid replacement
Hogan, T. F., Citrin, D. L., Johnson, B. M., Nakamura, S., Davis, T. E., & Borden, E. C. (1978) · Cancer · doi:10.1002/1097-0142(197811)42:5 · Cited by 72 · see citing works
HUMAN MACROVASCULAR ENDOTHELIAL CELLS: OPTIMIZATION OF CULTURE CONDITIONS
Terramani, T. T., Eton, D., BUI, P. A., WANG, Y., Weaver, F. A., & Yu, H. Y. (2000) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/1071-2690(2000)036 · Cited by 54 · see citing works
IKK-ϵ Coordinates Invasion and Metastasis of Ovarian Cancer
Hsu, S. C., Kim, M., Hernandez, L. F., Grajales, V., Noonan, A. M., Anver, M. R., Davidson, B., & Annunziata, C. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3993 · Cited by 49 · see citing works
Self-citation
Serum S100A6 Concentration Predicts Peritoneal Tumor Burden in Mice with Epithelial Ovarian Cancer and Is Associated with Advanced Stage in Patients
Wei, B., Hoover, S. B., Ross, M. M., Zhou, W., Meani, F., Edwards, J. B., Spehalski, E. I., Risinger, J. I., Alvord, W. G., Quiñones, O. A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007670 · Cited by 47 · see citing works
Reliable in vitro studies require appropriate ovarian cancer cell lines
Jacob, F., Nixdorf, S., Hacker, N. F., & Heinzelmann-Schwarz, V. A. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-60 · Cited by 45 · see citing works
Overexpression of protease inhibitor‐dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo
Devoogdt, N., Rasool, N., Hoskins, E. R., Simpkins, F. A., Tchabo, N. E., & Kohn, E. C. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01076.x · Cited by 41 · see citing works
Glucocorticoids Stabilize HER-2/neu Messenger RNA in Human Epithelial Ovarian Carcinoma Cells
Karklan, B. Y., Jones, J., Slamon, D. J., & Lagasse, L. D. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1090 · Cited by 37 · see citing works
Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C. M., Prentice, L., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a · Cited by 36 · see citing works
Analysis of the Rb Gene and Cyclin-Dependent Kinase 4 Inhibitor Genes (p16INK4and p15INK4B) in Human Ovarian Carcinoma Cell Lines
Yaginuma, Y., Hayashi, H., Kawai, K., Kurakane, T., Saitoh, Y., Kitamura, S., Sengoku, K., & Ishikawa, M. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3560 · Cited by 32 · see citing works
In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
House, C. D., Hernandez, L. F., & Annunziata, C. M. (2015) · Journal of Visualized Experiments · doi:10.3791/52446 · Cited by 28 · see citing works
Self-citation
Knowledge-driven genomic interactions: an application in ovarian cancer
Kim, D., Li, R., DUDEK, S. M., Frase, A., Pendergrass, S. A., & Ritchie, M. D. (2014) · BioData Mining · doi:10.1186/1756-0381-7-20 · Cited by 23 · see citing works
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Nuñez-Cruz, S., Connolly, D. C., & Scholler, N. (2010) · Journal of Visualized Experiments · doi:10.3791/2146 · Cited by 18 · see citing works
Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21
Kim, M. K., Min, D. J., Wright, G. W., Goldlust, I. S., & Annunziata, C. M. (2014) · Oncotarget · doi:10.18632/oncotarget.2665 · Cited by 14 · see citing works
Self-citation

Flagged first, then by citations

1 of the 43 references couldn’t be matched to a known paper.

Sorted by citations

Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms
van Weelden, G. H., Bobiński, M. S., Okła, K., van Weelden, W. J., Romano, A., & Pijnenborg, J. M. A. (2019) · Marine Drugs · doi:10.3390/md17010032 · Cited by 336 · see citing works
Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response
Rickard, B. P., Conrad, C., Sorrin, A. J., Ruhi, M. K., Reader, J. C., Huang, S. A., Franco, W., Scarcelli, G., Polacheck, W. J., Roque, D. M., et al. (2021) · Cancers · doi:10.3390/cancers13174318 · Cited by 154 · see citing works
Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas
Hallas-Potts, A., Dawson, J. C., & Herrington, C. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41941-4 · Cited by 110 · see citing works
Activation of Wnt signaling promotes olaparib resistant ovarian cancer
Yamamoto, T. M., McMellen, A. N., Watson, Z. L., Aguilera, J., Ferguson, R. L., Nurmemmedov, E., Thakar, T., Moldovan, G., Kim, H., Cittelly, D. M., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23064 · Cited by 95 · see citing works
NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem–like Cells
House, C. D., Jordan, E., Hernandez, L. F., Ozaki, M. K., James, J. M., Kim, M., Kruhlak, M. J., Batchelor, E., Elloumi, F., Cam, M. C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0366 · Cited by 91 · see citing works
Self-citation
Current Status of Patient-Derived Ovarian Cancer Models
Maru, Y., & Hippo, Y. (2019) · Cells · doi:10.3390/cells8050505 · Cited by 88 · see citing works
Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells
Robinson, M., Gilbert, S. F., Waters, J. A., Lujano-Olazaba, O., Lara, J., Alexander, L. J., Green, S. E., Burkeen, G., Patrus, O., Sarwar, Z., et al. (2021) · Cancers · doi:10.3390/cancers13020262 · Cited by 84 · see citing works
Self-citation
Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway
Islam, S. S., & Aboussekhra, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1360-3 · Cited by 74 · see citing works
Cell type‐selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment
Reinartz, S., Lieber, S., Pesek, J., Brandt, D. T., Asafova, A., Finkernagel, F., Watzer, B., Nockher, W. A., Nist, A., Stiewe, T., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12396 · Cited by 73 · see citing works
Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA
Sandhiutami, N. M. D., Arozal, W., Louisa, M., Rahmat, D., & Wuyung, P. E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603235 · Cited by 72 · see citing works
Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66 · see citing works
Drug resistance evaluation in novel 3D in vitro model
Nowacka, M., Sterzyńska, K., Andrzejewska, M., Nowicki, M. O., & Januchowski, R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111536 · Cited by 64 · see citing works
Autophagy gene haploinsufficiency drives chromosome instability, increases migration, and promotes early ovarian tumors
Delaney, J. R., Patel, C. B., Bapat, J., Jones, C. M., Zapatero, M. R., Ortell, K. K., Tanios, R., Haghighiabyaneh, M., Axelrod, J. L., DeStefano, J., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008558 · Cited by 55 · see citing works
Melatonin is a potential inhibitor of ovarian cancer: molecular aspects
Zare, H., Shafabakhsh, R., Reiter, R. J., & Asemi, Z. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0502-8 · Cited by 51 · see citing works
Alpha-Hederin, the Active Saponin of Nigella sativa, as an Anticancer Agent Inducing Apoptosis in the SKOV-3 Cell Line
Adamska, A., Stefanowicz‐Hajduk, J., & Ochocka, J. R. (2019) · Molecules · doi:10.3390/molecules24162958 · Cited by 49 · see citing works
Characteristics of in Vivo Model Systems for Ovarian Cancer Studies
Tudrej, P., Kujawa, K. A., Cortez, A. J., & Lisowska, K. M. (2019) · Diagnostics · doi:10.3390/diagnostics9030120 · Cited by 46 · see citing works
Simvastatin interferes with cancer ‘stem-cell’ plasticity reducing metastasis in ovarian cancer
Kato, S., Liberona, M., Cerda‐Infante, J., Sánchez, M., Henríquez, J., Bizama, C., Bravo, M. L. G., González, P., Gejman, R., Brañes, J. A., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0132 · Cited by 44 · see citing works
Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology
Brown, Y., Hua, S., & Tanwar, P. S. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.02.004 · Cited by 43 · see citing works
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
Ciucci, A., Buttarelli, M., Fagotti, A., Scambia, G., & Gallo, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04395-y · Cited by 43 · see citing works
The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary
Sneha, S., Nagare, R. P., Sidhanth, C., Krishnapriya, S., Garg, M., Ramachandran, B., Murhekar, K. M., Sundersingh, S., & Ganesan, T. S. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00504-w · Cited by 40 · see citing works
Mouse models of epithelial ovarian cancer for preclinical studies
Karakashev, S. V., & Zhang, R. (2021) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.382 · Cited by 38 · see citing works
Long non-coding RNA H19 mediates ovarian cancer cell cisplatin-resistance and migration during EMT.
Wu, Y., Zhou, Y., He, J., Sun, H., & Jin, Z. (2019) · Europe PMC (PubMed Central) · Cited by 35 · see citing works
A Novel Role for NUAK1 in Promoting Ovarian Cancer Metastasis through Regulation of Fibronectin Production in Spheroids
Fritz, J. L., Collins, O. M., Saxena, P., Buensuceso, A. V., Valdés, Y. R., Francis, K. E., Brown, K. R., Larsen, B. G., Colwill, K., Gingras, A., et al. (2020) · Cancers · doi:10.3390/cancers12051250 · Cited by 35 · see citing works
Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
Bortot, B., Mongiat, M., Valencic, E., Monego, S. D., Licastro, D., Crosera, M., Adami, G., Rampazzo, E., Ricci, G., Romano, F., et al. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s247114 · Cited by 33 · see citing works
STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway
Xu, S., Yue, Y., Zhang, S., Zhou, C., Cheng, X., Xie, X., Wang, X., & Lü, W. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0977-y · Cited by 33 · see citing works
Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors
Sanz, D. J., Raivola, J., Karvonen, H., Arjama, M., Barker, H. R., Murumägi, A., & Ungureanu, D. (2021) · Cancers · doi:10.3390/cancers13153727 · Cited by 31 · see citing works
Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites
Jones, M. R., Peng, P.-C., Coetzee, S. G., Tyrer, J. P., Reyes, A. L. P., Corona, R. I., Davis, B. D., Chen, S., Dezem, F. S., Seo, J.-H., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.08.021 · Cited by 25 · see citing works
Harnessing preclinical models for the interrogation of ovarian cancer
Qin, T., Fan, J., Lu, F., Zhang, L., Liu, C., Xiong, Q., Zhao, Y., Chen, G., & Sun, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02486-z · Cited by 28 · see citing works
Mitochondrial membrane depolarization enhances TRAIL-induced cell death in adult human granulosa tumor cells, KGN, through inhibition of BIRC5
MacDonald, J. A., Kura, N., Sussman, C., & Woods, D. C. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0463-3 · Cited by 26 · see citing works
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions
Dareng, E., Coetzee, S. G., Tyrer, J. P., Peng, P.-C., Rosenow, W. T., Chen, S., Davis, B. D., Dezem, F. S., Seo, J.-H., Nameki, R. A., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.04.011 · Cited by 25 · see citing works
The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines
Kaźmierczak, D., Jopek, K., Sterzyńska, K., Nowicki, M. O., Ruciński, M., & Januchowski, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010526 · Cited by 25 · see citing works
Anti‐HER2 Super Stealth Immunoliposomes for Targeted‐Chemotherapy
Canato, E., Grigoletto, A., Zanotto, I., Tedeschini, T., Campara, B., Quaglio, G., Toffoli, G., Mandracchia, D., Dinarello, A., Tiso, N., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301650 · Cited by 24 · see citing works
SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment
Zhu, Y., Borgogno, S. F., Sheng, J., Yeung, T.-L., Burks, J. K., Cappello, P., Jazaeri, A. A., Kim, J., Han, G. H., Birrer, M. J., et al. (2021) · Cancers · doi:10.3390/cancers13081777 · Cited by 24 · see citing works
Oncolytic activity of HF10 in head and neck squamous cell carcinomas
Esaki, S., Goshima, F., Ozaki, H., Takano, G., Hatano, Y., Kawakita, D., Ijichi, K., Watanabe, T., Sato, Y., Murata, T., et al. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0129-3 · Cited by 23 · see citing works
Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice
Brandon, A. D. H., Box, G., Hallsworth, A., Court, W. J., Matthews, N., Herodek, B., Bermejo-Arteagabeitia, A., Valenti, M. R., & Kirkin, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-67533-1 · Cited by 23 · see citing works
Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer
Koc, Z. C., Sollars, V. E., Zgheib, N. B., Rankin, G. O., & Koc, E. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1129352 · Cited by 22 · see citing works
Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer
Samec, T., Alatise, K. L., Boulos, J., Gilmore, S. N., Hazelton, A., Coffin, C., & Alexander-Bryant, A. A. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.012 · Cited by 21 · see citing works
Omental Preadipocytes Stimulate Matrix Remodeling and IGF Signaling to Support Ovarian Cancer Metastasis
Waters, J. A., Robinson, M., Lujano-Olazaba, O., Lucht, C., Gilbert, S. F., & House, C. D. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2613 · Cited by 20 · see citing works
Self-citation
Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells.
Santana‐Rivera, Y., Rabelo-Fernández, R. J., Quiñones‐Díaz, B. I., Grafals‐Ruiz, N., Santiago-Sánchez, G. S., Lozada-Delgado, E. L., Echevarría-Vargas, I. M., Apiz, J., Soto, D., Rosado, A., et al. (2020) · PubMed Central · Cited by 20 · see citing works
Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches
Zakarya, R., Howell, V. M., & Colvin, E. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134806 · Cited by 20 · see citing works
TWEAK–Fn14–RelB Signaling Cascade Promotes Stem Cell–like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse
Holmberg, R., Robinson, M., Gilbert, S. F., Lujano-Olazaba, O., Waters, J. A., Kogan, E., Velasquez, C. L. R., Stevenson, D., Cruz, L. S., Alexander, L. J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0486 · Cited by 19 · see citing works
Self-citation
Four and a Half LIM Domains 2 (FHL2) Contribute to the Epithelial Ovarian Cancer Carcinogenesis
Wang, C., Lv, X., He, C., Davis, J. S., Wang, C., & Hua, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207751 · Cited by 19 · see citing works
Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation
Yang, J., Liao, Q., Price, M., Moriarity, B. S., Wolf, N. K., Felices, M., Miller, J. S., Geller, M. A., Bendzick, L. E., Hopps, R., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101318 · Cited by 19 · see citing works
Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7Rα expression
Munoz, A., Urak, R. Z., Taus, E., Hsieh, H.-J., Awuah, D., Vyas, V., Lim, L., Jin, K., Lin, S., Priceman, S. J., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.017 · Cited by 18 · see citing works
The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: Insights from an in vitro model of collective detachment
Micek, H. M., Yang, N., Dutta, M., Rosenstock, L., Ma, Y., Hielsberg, C., McCord, M., Notbohm, J., McGregor, S. M., & Kreeger, P. K. (2024) · Science Advances · doi:10.1126/sciadv.adl4463 · Cited by 17 · see citing works
Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass
Straughn, A. R., Kelm, N., & Kakar, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.636498 · Cited by 15 · see citing works
UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer
Harrington, B. S., Kamdar, R. D., Ning, F., Korrapati, S., Caminear, M. W., Hernandez, L. F., Butcher, D. O., Edmondson, E. F., Traficante, N., Australian Ovarian Cancer Study Group, et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02820-z · Cited by 16 · see citing works
Self-citation
6-Plex mdSUGAR Isobaric-Labeling Guide Fingerprint Embedding for Glycomics Analysis
Ma, M., Li, M., Zhu, Y., Zhao, Y., Wu, F., Wang, Z., Yu, F., Chiang, H.-Y., Patankar, M. S., Chang, C., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c03342 · Cited by 16 · see citing works
A Systematic Comparative Assessment of the Response of Ovarian Cancer Cells to the Chemotherapeutic Cisplatin in 3D Models of Various Structural and Biochemical Configurations—Does One Model Type Fit All?
Gupta, P., Miller, A. F., Olayanju, A., Madhuri, T. K., & Velliou, E. G. (2022) · Cancers · doi:10.3390/cancers14051274 · Cited by 17 · see citing works
FAP is critical for ovarian cancer cell survival by sustaining NF-κB activation through recruitment of PRKDC in lipid rafts
Li, B., Ding, Z., Calbay, O., Li, Y., Li, T., Jin, L., & Huang, S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00575-x · Cited by 17 · see citing works
ONC201 induces the unfolded protein response (UPR) in high‐ and low‐grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity
Rumman, M., Buck, S. A., Polin, L., Dzinic, S. H., Boerner, J. L., & Winer, I. S. (2021) · Cancer Medicine · doi:10.1002/cam4.3858 · Cited by 14 · see citing works
Use of Transabdominal Ultrasound for the detection of intra-peritoneal tumor engraftment and growth in mouse xenografts of epithelial ovarian cancer
Chambers, L., Esakov, E. L., Braley, C., AlHilli, M. M., Michener, C. M., & Reizes, O. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228511 · Cited by 14 · see citing works
Melatonin Sensitizes OVCAR-3 Cells to Cisplatin through Suppression of PI3K/Akt Pathway
Baghal-Sadriforoush, S., Bagheri, M., Rad, I. A., & Sotoodehnejadnematalahi, F. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2022.68.4.19 · Cited by 14 · see citing works
Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium
Johnson, N., & Liao, J. B. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001115 · Cited by 12 · see citing works
Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism
Hernandez, L. F., Dull, A. B., Korrapati, S., & Annunziata, C. M. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00511-2 · Cited by 12 · see citing works
Self-citation
GBA inhibition suppresses ovarian cancer growth, survival and receptor tyrosine kinase AXL-mediated signaling pathways
Wang, G., Ouyang, B., Jing, F., & Dai, X. (2022) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2023.27.1.21 · Cited by 11 · see citing works
Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer
Paradiso, F., Lenna, S., Gazze, S. A., García-Parra, J., Murphy, K., Margarit, L., González, D., Francis, L. W., & Taraballi, F. (2022) · Cells · doi:10.3390/cells11050824 · Cited by 11 · see citing works
In vivo selection reveals autophagy promotes adaptation of metastatic ovarian cancer cells to abdominal microenvironment
Kuo, C.-L., Jiang, Z., Wang, Y., Lin, T., Huang, W., Wu, F., & Luo, C. (2019) · Cancer Science · doi:10.1111/cas.14162 · Cited by 11 · see citing works
The significance of interferon gamma inducible protein 16 (IFI16) expression in drug resistant ovarian cancer cell lines
Borucka, J., Sterzyńska, K., Kaźmierczak, D., Świerczewska, M., Nowacka, M., Wojtowicz, K., Klejewski, A., Nowicki, M. O., Zabel, M., Ramlau, R., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113036 · Cited by 10 · see citing works
A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling
Roggiani, F., Riva, C., Raspagliesi, F., Porta, G., Valli, R., Taramelli, R., Acquati, F., Mezzanzanica, D., & Tomassetti, A. (2019) · Cancers · doi:10.3390/cancers11020255 · Cited by 10 · see citing works
Identifying cell lines across pan-cancer to be used in preclinical research as a proxy for patient tumor samples
Bose, B., & Bozdag, S. (2024) · Communications Biology · doi:10.1038/s42003-024-06812-3 · Cited by 9 · see citing works
Three-Dimensional Model Analysis Revealed Differential Cytotoxic Effects of the NK-92 Cell Line and Primary NK Cells on Breast and Ovarian Carcinoma Cell Lines Mediated by Variations in Receptor–Ligand Interactions and Soluble Factor Profiles
Alekseeva, N. A., Boyko, A. A., Shevchenko, M. A., Grechikhina, M. V., Streltsova, M. A., Alekseeva, L. G., Sapozhnikov, A. M., Deyev, S. M., & Kovalenko, E. I. (2024) · Biomedicines · doi:10.3390/biomedicines12102398 · Cited by 9 · see citing works
Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer
Nair, J. R., Huang, T., Sunkara, A. D., Pruitt, M. R., Ibanez, K. R., Chiang, C.-Y., Cheng, K. C.-C., Wilson, K. M., Cardillo, T. M., Hofsess, S. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111283 · Cited by 9 · see citing works
Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma
Barbolina, M. V. (2022) · Cancers · doi:10.3390/cancers14184535 · Cited by 9 · see citing works
The overexpression of actin related protein 2/3 complex subunit 1B(ARPC1B) promotes the ovarian cancer progression via activation of the Wnt/β-catenin signaling pathway
Huang, J., Zhou, H., Tan, C., Mo, S., Liu, T., & Kuang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1182677 · Cited by 9 · see citing works
Molecular imaging-monitored radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy for rat orthotopic ovarian cancer
Li, Y., Zhao, S., Zhang, F., Jin, G., Zhou, Y., Li, P., Shin, D. S., & Yang, X. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1711973 · Cited by 9 · see citing works
The protease ADAMTS 5 controls ovarian cancer cell invasion, downstream of Rab25
Yuan, S., Bacchetti, R., Adams, J., Cuffaro, D., Rossello, A., Nuti, E., Santamaria, S., & Rainero, E. (2025) · FEBS Journal · doi:10.1111/febs.70080 · Cited by 8 · see citing works
Novel chromobox 2 inhibitory peptide decreases tumor progression
Brubaker, L. W., Backos, D. S., Nguyen, V., Reigan, P., Yamamoto, T. M., Woodruff, E. R., Iwanaga, R., Wempe, M. F., Kumar, V., Persenaire, C., et al. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2218614 · Cited by 8 · see citing works
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments
Villegas‐Vázquez, E. Y., Marín-Carrasco, F. P., Reyes‐Hernández, O. D., Báez-González, A. S., Bustamante-Montes, L. P., Padilla‐Benavides, T., Granados, L. I. Q., & Figueroa‐González, G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1514120 · Cited by 8 · see citing works
Deciphering the ghost proteome in ovarian cancer cells by deep proteogenomic characterization
Garcia-del Rio, D. F., Derhourhi, M., Bonnefond, A., Leblanc, S., Guilloy, N., Roucou, X., Eyckerman, S., Gevaert, K., Salzet, M., & Cardon, T. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07046-1 · Cited by 7 · see citing works
Targeting ATP Synthase by Bedaquiline as a Therapeutic Strategy to Sensitize Ovarian Cancer to Cisplatin
Zhu, H., Chen, Q., Zhao, L., & Hu, P. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2180825 · Cited by 7 · see citing works
Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance
Marolt, N., Pavlič, R., Kreft, T., Gjorgoska, M., & Rižner, T. L. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117069 · Cited by 7 · see citing works
Attenuated miR-203b-3p is critical for ovarian cancer progression and aptamer/miR-203b-3p chimera can be explored as a therapeutic
Li, T., Li, Y., Rehmani, H., Guo, J., Padia, R. N., Calbay, O., Ding, Z., Jiang, Y., Jin, L., & Huang, S. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100031 · Cited by 7 · see citing works
Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer
Kudo, K., Greer, Y. E., Crooks, D. R., Yang, Y., Brender, J., Yoshida, T., Harrington, B. S., Kamdar, R. D., Korrapati, S., Shibuya, Y., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07672-3 · Cited by 7 · see citing works
Self-citation
VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis
Waddell, S., Zhao, G., Liu, Z., Chen, H., Zhang, W., Wang, Y., Miller, D. D., Yue, J., & Li, W. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002298 · Cited by 6 · see citing works
Evaluation of effects of bisphenol analogs AF, S, and F on viability, proliferation, production of selected cancer-related factors, and expression of selected transcripts in Caov-3 human ovarian epithelial cell line
Mlynarčíková, A. B., & Scsuková, S. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.114889 · Cited by 6 · see citing works
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
Shen, Y. T., Wang, L. L., Evans, J. C., Allen, C. J., & Piquette‐Miller, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102498 · Cited by 6 · see citing works
Investigation of Physiological Effects Induced by Dehydroepiandrosterone in Human Endothelial Cells and Ovarian Cancer Cell Line
Gündoğan, G. İ., Kığ, C., Karacan, M., & Doğruman, H. (2020) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2020.58827 · Cited by 6 · see citing works
UBP43 promotes epithelial ovarian carcinogenesis via activation of β‐catenin signaling pathway
Xie, H., Chen, J., Ma, C., Zhao, J., & Cui, M. (2023) · Cell Biology International · doi:10.1002/cbin.12028 · Cited by 6 · see citing works
Spheroid architecture strongly enhances miR-221/222 expression and promotes oxidative phosphorylation in an ovarian cancer cell line through a mechanism that includes restriction of miR-9 expression
Ward, A. S., Hall, C. N., Tree, M. O., & Kohtz, D. S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09168-9 · Cited by 6 · see citing works
The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines
Wojtowicz, K., Świerczewska, M., Nowicki, M. O., & Januchowski, R. (2023) · Advances in Medical Sciences · doi:10.1016/j.advms.2023.09.013 · Cited by 4 · see citing works
Effect of overexpression of Rac1 on radiosensitivity of nasopharyngeal carcinoma xenografts in nude mice, and the underlying mechanism
Liao, K., Zheng, R., Feng, J., Liu, H., & Xie, G. (2023) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v22i4.11 · Cited by 4 · see citing works
A Novel Role of Connective Tissue Growth Factor in the Regulation of the Epithelial Phenotype
Gogoi, R. P., Galoforo, S., Fox, A. L., Morris, C., Ramos, H., Gogoi, V., Chehade, H., Adzibolosu, N. K., Shi, C., Zhang, J., et al. (2023) · Cancers · doi:10.3390/cancers15194834 · Cited by 4 · see citing works
CTDPathSim
Bose, B., & Bozdag, S. (2020) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/3388440.3412456 · Cited by 3 · see citing works
Exploring the role of estrogens and steroid sulfatase inhibition in platinum resistance, proliferation, migration, and cell death in high-grade serous ovarian cancer cells
Marolt, N., Potter, B. V. L., & Rižner, T. L. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118278 · Cited by 2 · see citing works
Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screens
Skipper, T. S., Dickson, K.-A., Denes, C. E., Waller, M. A., Du, T. Y., Neely, G., Bowden, N., Faiz, A., & Marsh, D. J. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01102-4 · Cited by 2 · see citing works
Prolyl-isomerase Pin1 drives platinum resistance by regulating Notch3 stability and function in ovarian cancer
Giuli, M. V., Mancusi, A., Natiello, B., Cristofano, S. D., Reali, R., Pignataro, M. G., D’Andrea, D., Magno, L. D., Nicoletti, C., Giorgi, A., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03658-x · Cited by 2 · see citing works
Circ-RNF111 Promotes Proliferation of Ovarian Cancer Cell SKOV-3 by Targeting the MiR-556-5p/CCND1 Axis
Zuo, L., Tan, Y., Xu, Q., Li, X., & Mi, X. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10665-0 · Cited by 2 · see citing works
The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines
Nowacka, M., Ginter-Matuszewska, B., Świerczewska, M., Nowicki, M. O., Zabel, M., Sterzyńska, K., & Januchowski, R. (2021) · Medical Journal of Cell Biology · doi:10.2478/acb-2021-0019 · Cited by 2 · see citing works
Cancer Study: Cell to the Animal Models
Amălinei, C., Grigoraş, A., Pricope, D. L., & Pricop, B.-I. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_2 · Cited by 2 · see citing works
Deep learning on image-omics data in identifying prognostic immune biomarkers for ovarian cancerPreprint
Zhu, Y., Borgogno, S. F., Sheng, J., Yeung, T.-L., Burks, J. K., Cappello, P., Jazaeri, A. A., Kim, J., Han, G. H., Birrer, M., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-67036/v1 · Cited by 2 · see citing works
Models of High-Grade Serous Ovarian CarcinomaPreprint
Pundel, O. J., & Neel, B. G. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041949 · Cited by 2 · see citing works
Bioimpedance Spectroscopy for Noninvasive Monitoring of Tumor Spheroids
Khattab, A., Grabowski, R., Oenning, L., Schmees, C., & Zeck, G. M. (2024) · International Workshop on Impedance Spectroscopy (IWIS) · doi:10.1109/iwis63047.2024.10847237 · Cited by 1 · see citing works
Orientation of Preclinical Research in Ovarian Cancer
Baert, T., Garg, A. D., Agostinis, P., Vergote, I. B., & Coosemans, A. (2017) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001053 · Cited by 1 · see citing works
Dual Targeting of Mitochondrial Membrane Potential and XIAP by Mebendazole Triggers Apoptosis in Ovarian Cancer Cells: An Integrated In Vitro and In Silico Perspective
Gupta, R. K. (2025) · DNA and cell biology reports. · doi:10.1177/29979811251379351 · Cited by 1 · see citing works
Investigating different type of ovary cancer cell line for NK cell in vitro co-culture cytotoxic assay
Pangjaya, L. F., Khaerunnisa, S., Mazfufah, N. F., Budiman, R. L., & Antarianto, R. D. (2021) · AIP conference proceedings · doi:10.1063/5.0049155 · Cited by 1 · see citing works
Finding the best cell lines across pan-cancer to use in pre-clinical research as a proxy for patient tumor samples considering immune cells, multi-omics, and cancer pathwaysPreprint
Bose, B., & Bozdag, S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.18.520831 · Cited by 1 · see citing works
CTDPathSim: Cell line-tumor deconvoluted pathway-based similarity in the context of precision medicine in cancer *Preprint
Bose, B., & Bozdag, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.13.149666
Models of ovarian cancer to test new agents
Sodi, V. L., Craig, A. D., Peri, S., & Connolly, D. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00012-1
Melatonin Sensitize the Ovarian Cancer Cells to Cisplatin through suppression of PI3K/Akt pathwayPreprint
Baghal-Sadriforoush, S., Bagheri, M., Rad, I. A., & Sotoodehnejadnematalahi, F. (2021) · Research Square · doi:10.21203/rs.3.rs-497936/v1

Abstract B43: Characterization of ovarian cancer cells as in vivo models for preclinical studies.
Hernandez, L. F., Kim, M. K., Lyle, L. T., Steeg, P. S., & Annunziata, C. M. (2016) · Clinical Cancer Research · doi:10.1158/1557-3265.ovca15-b43
Self-citation
Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer
Shaw, T. J., Senterman, M. K., Dawson, K. M., Crane, C. A., & Vanderhyden, B. C. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.013 · Cited by 278 · see citing works
In vivo tumor growth of high-grade serous ovarian cancer cell lines
Mitra, A. K., Davis, D. A., Tomar, S., Roy, L., Main, H. G., Xie, J., Lantvit, D. D., Cárdenas, H., Fang, F., Liu, Y., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.040 · Cited by 214 · see citing works
Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease
Sauriol, S. A., Simeone, K., Portelance, L., Meunier, L., Leclerc-Desaulniers, K., de Ladurantaye, M., Chergui, M., Kendall‐Dupont, J., Rahimi, K., Carmona, E., et al. (2020) · Cancers · doi:10.3390/cancers12082222 · Cited by 15 · see citing works
Abstract 1979: Cell lines that genomically resemble high-grade serous ovarian carcinomas display differences in growth and invasive capacities in an orthometastatic nude mouse model
Alghamdi, S., Goyeneche, A. A., Gao, Z., & Telleria, C. M. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-1979

Authors: Hernandez, L., Kim, M. K., Lyle, L. T., Bunch, K. P., House, C. D., Ning, F., Noonan, A. M., & Annunziata, C. M.
Affiliations: National Cancer Institute (US)
Corresponding author: Annunziata, Christina M.
ORCID: Lyle, L. Tiffany
Bunch, Kristen P.
House, Carrie D.
Ning, Franklin
Noonan, Anne M.
Annunziata, Christina M.
Venue: Gynecologic Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 142
Issue: 2
Pages: 332-340
ISSN: 0090-8258 (ISSN-L)
DOI: 10.1016/j.ygyno.2016.05.028
PMC: PMC4961516
OpenAlex: W2399911066
Cited by: 121
References: 43
Citations by year: 2026: 10 · 2025: 10 · 2024: 15 · 2023: 16 · 2022: 17 · 2021: 15 · 2020: 17 · 2019: 14 · 2018: 4 · 2017: 3
FWCI: 9.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gynecologic Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute Intramural Research Program (ZIA BC 011054)
Topics: Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
Keywords: ovarian cancer cell lines, in vivo tumorigenicity, xenograft models, nude mice, subcutaneous implantation, intraperitoneal implantation, gene expression profiling, proteomic profiling, preclinical model selection
MeSH terms: Animals, Drug Screening Assays, Antitumor, Female, Humans, Neoplasm Transplantation, Ovarian Neoplasms, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Characterization of Ovarian Cancer Cell Lines as In Vivo Models for Preclinical Studies

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks